Retinalgenix Technologies Stock Performance
| RTGN Stock | USD 3.20 0.00 0.00% |
The company holds a Beta of 0.91, which implies possible diversification benefits within a given portfolio. RetinalGenix Technologies returns are very sensitive to returns on the market. As the market goes up or down, RetinalGenix Technologies is expected to follow. At this point, RetinalGenix Technologies has a negative expected return of -0.14%. Please make sure to check RetinalGenix Technologies' market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and rate of daily change , to decide if RetinalGenix Technologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days RetinalGenix Technologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest fragile performance, the Stock's technical and fundamental indicators remain healthy and the recent disarray on Wall Street may also be a sign of long period gains for the firm investors. ...more
RetinalGenix |
RetinalGenix Technologies Relative Risk vs. Return Landscape
If you would invest 354.00 in RetinalGenix Technologies on October 15, 2025 and sell it today you would lose (34.00) from holding RetinalGenix Technologies or give up 9.6% of portfolio value over 90 days. RetinalGenix Technologies is currently does not generate positive expected returns and assumes 2.0583% risk (volatility on return distribution) over the 90 days horizon. In different words, 18% of otc stocks are less volatile than RetinalGenix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
RetinalGenix Technologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for RetinalGenix Technologies' investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as RetinalGenix Technologies, and traders can use it to determine the average amount a RetinalGenix Technologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0689
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RTGN |
Based on monthly moving average RetinalGenix Technologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of RetinalGenix Technologies by adding RetinalGenix Technologies to a well-diversified portfolio.
RetinalGenix Technologies Fundamentals Growth
RetinalGenix OTC Stock prices reflect investors' perceptions of the future prospects and financial health of RetinalGenix Technologies, and RetinalGenix Technologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on RetinalGenix OTC Stock performance.
| Return On Asset | -49.71 | |||
| Current Valuation | 155.49 M | |||
| Shares Outstanding | 17.27 M | |||
| EBITDA | (2.18 M) | |||
| Cash And Equivalents | 27 | |||
| Total Debt | 114.69 K | |||
| Book Value Per Share | (0.06) X | |||
| Cash Flow From Operations | (1.17 M) | |||
| Earnings Per Share | (0.05) X | |||
| Total Asset | 4.95 K | |||
| Retained Earnings | (8.81 M) | |||
| Current Asset | 11.77 M | |||
| Current Liabilities | 575 K | |||
About RetinalGenix Technologies Performance
By examining RetinalGenix Technologies' fundamental ratios, stakeholders can obtain critical insights into RetinalGenix Technologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that RetinalGenix Technologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
RetinalGeniX Technologies, Inc., an ophthalmic research and development company, focuses on developing technologies to screen, monitor, diagnose, and treat ocular, optical, and sight-threatening disorders. RetinalGenix Technologies Inc. is a subsidiary of Sanovas Ophthalmology, LLC. Retinalgenix Technologies operates under Medical Devices classification in the United States and is traded on OTC Exchange.Things to note about RetinalGenix Technologies performance evaluation
Checking the ongoing alerts about RetinalGenix Technologies for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for RetinalGenix Technologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| RetinalGenix Technologies generated a negative expected return over the last 90 days | |
| Net Loss for the year was (2.18 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| RetinalGenix Technologies currently holds about 27 in cash with (1.17 M) of positive cash flow from operations. | |
| Roughly 66.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing RetinalGenix Technologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether RetinalGenix Technologies' stock is overvalued or undervalued compared to its peers.
- Examining RetinalGenix Technologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating RetinalGenix Technologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of RetinalGenix Technologies' management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of RetinalGenix Technologies' otc stock. These opinions can provide insight into RetinalGenix Technologies' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in RetinalGenix OTC Stock
RetinalGenix Technologies financial ratios help investors to determine whether RetinalGenix OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in RetinalGenix with respect to the benefits of owning RetinalGenix Technologies security.